Real-World Safety and Effectiveness of Sotyktu (Deucravacitinib) in Patients With Moderate-to-Severe Plaque Psoriasis in Korea

Moderate-to-severe Plaque Psoriasis Clinical Trial

Official title:
Sotyktu (Deucravacitinib) Post-Marketing Surveillance in Korean Patients With Moderate-to-Severe Plaque Psoriasis

Status Not yet recruiting

Clinical Trial Summary

The purpose of this observational study is to describe the safety and effectiveness of deucravacitinib in participants in Korea that have been diagnosed with moderate-to-severe plaque psoriasis.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Moderate-to-severe Plaque Psoriasis
Psoriasis

Clinical Trial Details

NCT number	NCT06258668
Study type	Observational
Source	Bristol-Myers Squibb
Contact	BMS Study Connect Contact Center www.BMSStudyConnect.com
Phone	855-907-3286
Email	Clinical.Trials@bms.com
Status	Not yet recruiting
Phase
Start date	July 1, 2024
Completion date	December 1, 2028

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT05787236` - A Study of Moderate-to-severe Plaque Psoriasis Patients Response to Secukinumab Treatment in Real-world Setting
Active, not recruiting	`NCT04612699` - A Phase 2 Study of Jaktinib in Participants With Moderate to Severe Psoriasis	Phase 2
Recruiting	`NCT06142357` - Secukinumab Drug Survival, Effectiveness and Tolerability in Pediatric Patients With Psoriasis
Completed	`NCT06182384` - A Clinical Study to Compare the Safety and Pharmacokinetics of SHR-1314 Injection in Healthy Subjects at Different Specifications Devices	Phase 1
Recruiting	`NCT03710681` - A Safety Study of Multiple Subcutaneous (s.c.) Injections of SHR-1314 in Adults With Moderate-to-severe Plaque Psoriasis	Phase 1
Not yet recruiting	`NCT04839016` - Efficacy 、Safety and PK of SHR-1314 in Patients With Moderate-to-Severe Plaque Psoriasis	Phase 3